These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17636697)

  • 21. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
    Calcutt NA; Freshwater JD; Mizisin AP
    Diabetologia; 2004 Apr; 47(4):718-24. PubMed ID: 15298349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
    Hamada Y; Nakamura J
    Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
    Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
    Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
    Cameron NE; Cotter MA; Robertson S
    Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
    Pfeifer MA
    Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
    Florkowski CM; Rowe BR; Nightingale S; Harvey TC; Barnett AH
    Diabetes; 1991 Jan; 40(1):129-33. PubMed ID: 1901808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
    Jaspan J; Maselli R; Herold K; Bartkus C
    Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Wakao T; Sasaki H; Mori K; Nakashima E; Naruse K; Hotta N
    Life Sci; 1997; 60(21):1847-57. PubMed ID: 9154994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
    Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.